CN119367341A - 采用ralinepag与其他药剂的组合治疗pah的方法 - Google Patents

采用ralinepag与其他药剂的组合治疗pah的方法 Download PDF

Info

Publication number
CN119367341A
CN119367341A CN202411493404.9A CN202411493404A CN119367341A CN 119367341 A CN119367341 A CN 119367341A CN 202411493404 A CN202411493404 A CN 202411493404A CN 119367341 A CN119367341 A CN 119367341A
Authority
CN
China
Prior art keywords
ralinepag
medicament
pah
formulated
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411493404.9A
Other languages
English (en)
Chinese (zh)
Inventor
卢西·H·克拉普
D·P·贝汉
约翰·W·亚当姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CN119367341A publication Critical patent/CN119367341A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN202411493404.9A 2016-11-10 2017-11-10 采用ralinepag与其他药剂的组合治疗pah的方法 Pending CN119367341A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662420515P 2016-11-10 2016-11-10
US62/420,515 2016-11-10
US201762530533P 2017-07-10 2017-07-10
US62/530,533 2017-07-10
PCT/US2017/061116 WO2018089804A1 (en) 2016-11-10 2017-11-10 Methods of treating pah with combinations of ralinepag and other agents
CN201780082981.0A CN110691612B (zh) 2016-11-10 2017-11-10 采用ralinepag与其他药剂的组合治疗pah的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780082981.0A Division CN110691612B (zh) 2016-11-10 2017-11-10 采用ralinepag与其他药剂的组合治疗pah的方法

Publications (1)

Publication Number Publication Date
CN119367341A true CN119367341A (zh) 2025-01-28

Family

ID=60451197

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780082981.0A Active CN110691612B (zh) 2016-11-10 2017-11-10 采用ralinepag与其他药剂的组合治疗pah的方法
CN202411493404.9A Pending CN119367341A (zh) 2016-11-10 2017-11-10 采用ralinepag与其他药剂的组合治疗pah的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201780082981.0A Active CN110691612B (zh) 2016-11-10 2017-11-10 采用ralinepag与其他药剂的组合治疗pah的方法

Country Status (10)

Country Link
US (1) US12377067B2 (enExample)
EP (1) EP3538154B1 (enExample)
JP (3) JP2019533713A (enExample)
KR (3) KR20240068077A (enExample)
CN (2) CN110691612B (enExample)
AU (2) AU2017357759A1 (enExample)
CA (1) CA3043283A1 (enExample)
IL (2) IL266518A (enExample)
MA (1) MA46750A (enExample)
WO (1) WO2018089804A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240068077A (ko) 2016-11-10 2024-05-17 아레나 파마슈티칼스, 인크. 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
WO2018160882A1 (en) 2017-03-01 2018-09-07 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
US12433865B2 (en) * 2018-05-16 2025-10-07 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
CN108721296B (zh) * 2018-07-03 2019-04-05 中国人民解放军总医院 一种化合物在治疗或预防高原病中的用途
CN112638865B (zh) * 2018-09-06 2022-07-26 广东东阳光药业有限公司 药物共晶体及其制备方法
SI3897646T1 (sl) * 2018-12-21 2024-08-30 ACTELION PHARMACEUTICALS lTD, Makitentan za zdravljenje pljučne arterijske hipertenzije
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
CN118922402A (zh) 2022-02-15 2024-11-08 联合治疗公司 结晶前列环素(ip)受体激动剂及其用途
US20250282716A1 (en) 2024-03-11 2025-09-11 United Therapeutics Corporation Methods of making ip-receptor agonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085844A1 (en) 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
WO2002055484A1 (en) 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Biaryl compound, process for producing the same, and agent
WO2003007888A2 (en) 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
RU2315746C2 (ru) 2001-08-09 2008-01-27 Оно Фармасьютикал Ко., Лтд. Производные карбоновых кислот и фармацевтическое средство, содержащее их в качестве активного ингредиента
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TWI293715B (en) 2002-10-10 2008-02-21 Sipix Imaging Inc A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display
WO2004072038A1 (en) 2003-02-10 2004-08-26 Vertex Pharmaceuticals Incorporated Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
WO2006023844A2 (en) 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
WO2007051255A1 (en) 2005-11-04 2007-05-10 The University Of Sydney Process for the preparation of compounds containing an azacyclic ring system
EA200802213A1 (ru) 2006-05-09 2009-10-30 Химекуэст Фармасьютикалз, Инк. Способы лечения заболеваний крови
WO2009117095A1 (en) 2008-03-18 2009-09-24 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
NZ593002A (en) 2008-11-26 2013-08-30 Arena Pharm Inc Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
US8940891B2 (en) 2008-12-08 2015-01-27 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
EP2480526A1 (en) * 2009-09-23 2012-08-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
US9388154B2 (en) 2011-09-12 2016-07-12 Lund Biotechnology PBC Process for preparing synthetic prostacyclins
KR20150089087A (ko) * 2012-11-30 2015-08-04 인스메드 인코포레이티드 프로스타사이클린 조성물 및 이를 이용하기 위한 방법
US10537546B2 (en) 2014-10-23 2020-01-21 Arena Pharmaceuticals, Inc. Method of treating conditions related to the PGI2 receptor
MX2017009110A (es) * 2015-01-13 2017-11-09 Vivus Inc Terapia de combinacion para hipertension pulmonar.
KR20240068077A (ko) 2016-11-10 2024-05-17 아레나 파마슈티칼스, 인크. 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법

Also Published As

Publication number Publication date
MA46750A (fr) 2019-09-18
AU2017357759A1 (en) 2019-06-06
IL323354A (en) 2025-11-01
JP2019533713A (ja) 2019-11-21
AU2023263497B2 (en) 2025-09-18
KR20230021186A (ko) 2023-02-13
US20190321328A1 (en) 2019-10-24
EP3538154A1 (en) 2019-09-18
JP2023029865A (ja) 2023-03-07
CA3043283A1 (en) 2018-05-17
US12377067B2 (en) 2025-08-05
WO2018089804A1 (en) 2018-05-17
KR20200015439A (ko) 2020-02-12
AU2023263497A1 (en) 2023-11-30
IL266518A (en) 2019-07-31
CN110691612B (zh) 2024-11-08
CN110691612A (zh) 2020-01-14
WO2018089804A9 (en) 2018-06-21
KR20240068077A (ko) 2024-05-17
JP2025131627A (ja) 2025-09-09
EP3538154B1 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
CN110691612B (zh) 采用ralinepag与其他药剂的组合治疗pah的方法
Barnett DPP‐4 inhibitors and their potential role in the management of type 2 diabetes
Goldenberg Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction
Flynn et al. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension
Ahrén Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin–diabetes control and potential adverse events
US20070197544A1 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
KR20190017936A (ko) 리나글립틴 및 메트포르민의 병용물
JP2852043B2 (ja) 安定化薬剤組成物
US20040110747A1 (en) Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
Galiè et al. Emerging medical therapies for pulmonary arterial hypertension
Meier et al. The future of angiotensin II inhibition in cardiovascular medicine
Borghi et al. Zofenopril: Blood pressure control and cardio-protection
JP7758655B2 (ja) 組合せ
US20050197332A1 (en) Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
RU2182002C2 (ru) Композиция с фиксированной дозой ингибитора ангиотензин-превращающего фермента и антагониста кальциевых каналов, способ ее изготовления и применение для лечения сердечно-сосудистых заболеваний
Forman et al. Vasoactive and antiplatelet agents
US6284790B1 (en) Methods of potentiating organic nitrates having vasodilating activity and formulations for the same
US20100249103A1 (en) combination treatment
Sniecinski et al. Cardiovascular pharmacology
Martres HM74a agonists: will they be the new generation of nicotinic acid?
KR102042456B1 (ko) 경피흡수제제
Kaushik et al. Overture of the sildenafil citrate gels and jellies: The simplified sight
Lambova Treatment of Raynaud s Phenomenon
IT8922129A1 (it) Impiego dell'isosorbide 2-mononitrato per la preparazione di composizioni farmaceutiche atte al trattamento dell'angina pectoris
MXPA06003273A (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination